News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
running nicely on article out very thin https://www.zerohedge.com/news/2023-03-07/sick-jabs-and-rebounds-breakthrough-antiviral-flushes-out-multiple-viruses
New article out on Zerohedge highlighting ProLectin. Drug is pretty promising. Especially since the ritonavir in Paxlovid means that Paxlovid won't be a good idea for long COVID. ProLectin is the best approach for Long COVID I've seen. But also potentially the best antiviral for acute COVID too, as explained in the article.
https://www.zerohedge.com/news/2023-03-07/sick-jabs-and-rebounds-breakthrough-antiviral-flushes-out-multiple-viruses
Green alert $Bixt talks in 4 mins Long Haul Covid19 antiviral
https://www.youtube.com/watch?v=EsHs0QLaWvc
When? All it takes is one whale, or leader of whales $$$$$$ to see what $BIXT has hiding out down here on OTC, specifically a whole new class on totally non toxic, antivirals that can be the next Moderna IMO.
I was one of the first to tell folks what a huge deal Moderna was in Feb 2020, and at the time it was still a no revenue, super cash eater experiment..... that became the holy grail of Covid19 rapid to market vaccines, FDA Warp Speed same humanity pandemic solver in a year, that use to take 10 years and 1/2 Billion dollars of major risk takers...to get to market.
Just need to right eyes on $BIXT.
It will happen. And maybe just as fast as Moderna, since the costs are lower and process is faster in India... and the market is massive in Asia...
The facility in India is FDA inspected, where the trial drug is made BTW...
In 1-2 years it is possible, they get bought out for Billions, or get a JV marketing / distribution deal with a Moderna or Pfizer or Novartis IMO....
Huge, major mega monster behemoth news out. $BIXT just approved for an IND Investigational New Drug Application trial for Long Haul Covid. Earlier $BIXT trials for covid19 outperformed Paxlovid, with 100% elimination of all measurable levels of Covid19 in the blood in as little as 3 days.
Almost no eyes on this story yet folks, 2022 high was $1.25
Lets go!!!!
https://www.otcmarkets.com/filing/html?id=16366618&guid=Jq2-kHEYY764dth
"ProLectin-I is an intravenous new chemical entity drug that is expected to treat Long COVID and Idiopathic Pulmonary Fibrosis (IPF). Long COVID is estimated to have 65 – 100 million cases worldwide. (1, 2) The CDC believes it affects one in five people that contract COVID-19. According to Harvard University, the economic cost of Long COVID is $3.7 trillion in the just the United States. IPF affects approximately 3 million people worldwide. (4) The disease primarily affects patients over the age of 50 and affects more men than women.
The top theory behind the pathogenesis of Long Covid is viral persistence (6) or viral fragments. ProLectin-I binds to the ‘galectin fold’ of the spike protein thereby neutralizing a replication competent viruses’ ability to infect other cells, but it also binds to spike protein fragments thought to be the cause of ongoing inflammation.
The medical term for scar tissue is fibrin. The word fibrosis stems from the continued growth of fibrin. Once scar tissue forms in the lungs combined with an already suppressed immune system, scar tissue can start to spread quickly.
The reason for scar tissue forming in the lungs can vary, but it can always be associated with the onset of lung damage.
Combining lung damage with an impaired immune system leads to scar tissue forming in the lungs. Multiple galectin types are associated with fibrosis, and ProLectin-I is thought to bind to a few."
She's moving $BIXT
Pop coming?
China steals technology. That is why companies with any sense are leaving.
BIXT is on a fast track in India, so I have no clue what nonsense you are talking about regarding India taking it slow with the $BIXT Galectin antivirals technology.
$BIXT Update on the failing badly competition
POLITICO: Once-favored Covid drugs ineffective on Omicron may be putting millions at risk.
https://www.politico.com/news/2023/01/01/omicron-covid-antibody-drugs-immunocompromised-00075285
Time to load the boat with $BIXT
Things are heating up fast in the US again
CNN: Omicron offshoot XBB.1.5 could drive new Covid-19 surge in US.
https://www.cnn.com/2023/01/03/health/covid-variant-xbb-explainer/index.html
This has Moderna Billion dollar + market cap start up written all over it. IMO, this tech will eclipse Moderna's
over the next 2-3 years...
Here is why:
https://microcapdaily.com/bioxytran-inc-otcmkts-bixt-crushes-primary-endpoint-expected-to-achieve-unicorn-status-in-new-year/
Happy New Year folks.
$BIXT has a one hell of a bright future, just like I said Moderna did in March 2020 before it's share price exploded
BioXyTran Inc. is a biotech company that has recently announced positive results from a clinical trial of its COVID-19 antiviral drug, ProLectin-M. The trial showed that the drug was able to completely eliminate the virus in 100% of patients by day 7 and in 88% of patients by day 3. The drug works by blocking the viral docking of the virus to target cells, rather than by blocking viral replication from the inside, and is taken orally. BioXyTran has a strong background in carbohydrate chemistry and was able to pivot towards developing a carbohydrate-based antiviral for COVID-19 during the beginning of the pandemic. The company has faced adversity, including being suspended by the SEC and defaulting on debt, but has managed to regain trading status and secure backing from private equity and high-net-worth individuals. The potential success of ProLectin-M could have significant impact on the market for antivirals and on BioXyTran's valuation.
|
Followers
|
44
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1222
|
|
Created
|
03/23/10
|
Type
|
Free
|
| Moderators | |||
